Premium
Serine protease inhibitor lymphoepithelial Kazal type‐related inhibitor tends to be decreased in atopic dermatitis
Author(s) -
Roedl D,
TraidlHoffmann C,
Ring J,
Behrendt H,
BraunFalco M
Publication year - 2009
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2009.03302.x
Subject(s) - atopic dermatitis , allergy , medicine , dermatology , immunology
A pathogenic role of serine protease inhibitor lymphoepithelial Kazal type-related inhibitor (LEKTI) in atopic dermatitis (AD) is currently in intense debate. Analyses of an association between genetic polymorphisms of SPINK5 and atopic diseases revealed contradictory results. Herein, we assessed the role of LEKTI in AD at an expressional and functional level.